Researchers from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore suggest that controlling the costs to treat cancer without increasing risk to patients requires a collaborative approach.
Researchers from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore suggest that controlling the costs to treat cancer without increasing risk to patients requires a collaborative approach.
“We argue that the FDA, Medicare, insurance companies, the public, and the pharmaceutical companies have to come to some agreement. Competitive bidding by hospitals and health systems should be used to drive prices lower,” say researchers Ronan J. Kelly, MD, MBA, and Thomas J. Smith, MD. “We are sympathetic to drug companies that want to charge enough to generate enough return of the cost of investigation, but we need transparency regarding the cost of development. Some drugs can cost a billion to develop, perhaps, but not every one. There has to be some way to relate the price of the drug to the value of the drug. And we have to set limits.”
Drs Kelly and Smith add that hospitalization, imaging, and drug costs can all specifically be targeted.
Medical imaging such as positron emission tomography—or PET scans—while helpful, have not been shown to provide any more effective benefits or results than other less-costly examinations. As well, services such as hospice care can provide better care and quality of life at lower costs than hospitalization. In particular, however, they suggest that addressing drug costs will be the most essential.
“We'll get to a situation where only the richest of the rich can afford these drugs, and we will have a lot of people looking on from the sidelines,” say the researchers.
“There are drugs that cost tens of thousands of dollars with an unbalanced relationship between cost and benefit. We need to determine appropriate prices for drugs and inform patients about their costs of care,” explains Dr Smith.
Cancer drug spending is projected to increase nearly 40% by 2020 as new diagnoses of the disease in the United States continue to increase. Such trends require healthcare stakeholders to change practice patterns and to think more cost-effectively.
Around the Web
Three Ways to Make Cancer Care More Affordable [National Geographic]
US Cancer Care Researchers Say "Cut Drug Prices" [PharmaTimes]
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Community Engagement, Culturally Tailored Care as a Gateway to Advancing Health Equity
October 16th 2024Many talks at the Association of Cancer Care Centers (ACCC) 41st National Oncology Conference advocated for the adoption of culturally relevant care, the leveraging of community partnerships, and community engagement to build better trust with patients and improve outcomes.
Read More
Combatting Misconceptions of Clinical Trials to Improve Patient Participation
October 16th 2024There are many misconceptions patients might have about clinical trials that prevent them from participating, and it’s important to understand what they are in order to overcome them, said Terry L. Keys, of University of Kentucky Markey Cancer Center.
Read More